Efficacy and Safety of Topical Sirolimus for the Treatment of Angiofibromas in Tuberous Sclerosis: a Systematic Review and Meta-analysis
- 13 December 2023
- journal article
- review article
- Published by Springer Nature in Current Pharmacology Reports
- Vol. 10 (1) , 68-83
Abstract
No abstract availableKeywords
All Related Versions
This publication has 43 references indexed in Scilit:
- Topical Rapamycin Therapy to Alleviate the Cutaneous Manifestations of Tuberous Sclerosis ComplexDrugs in R&D, 2012
- Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: A pilot study of four patientsAustralasian Journal of Dermatology, 2011
- Sirolimus in pediatric renal transplantationPediatric Transplantation, 2011
- A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severityBritish Journal of Dermatology, 2011
- New technique using combined pulsed dye laser and fractional resurfacing for treating facial angiofibromas in tuberous sclerosisLasers in Surgery and Medicine, 2010
- Treatment of Angiofibromas of Tuberous Sclerosis with 5-Aminolevulinic Acid Blue Light Photodynamic Therapy Followed by Immediate Pulsed Dye LaserDermatologic Surgery, 2009
- Sirolimus (rapamycin): From the soil of Easter Island to a bright futureJournal of the American Academy of Dermatology, 2007
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006
- Molecular activity of sirolimus and its possible application in tuberous sclerosis treatmentMedicinal Research Reviews, 2005
- Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatologyClinical and Experimental Dermatology, 2002